- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04580667
Prospective Observational Exploratory Clinical Study to Determine the Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict Gastrointestinal Radiation Toxicity Using Circulating Cell Free DNA Directly From Plasma
September 6, 2023 updated by: DiaCarta, Inc.
This clinical study is conducted to develop a new test to identify prostate cancer patients at highest risk of radiotherapy-related complications, especially related to gastrolintestinal (GI) toxicities.
This clinical study would allow monitoring of total tissue damage in blood samples as early as after the 2nd but before the 4th radiotherapy dose during week 1 of radiotherapy, which could help clinicians make treatment decisions.
Detection of excessive tissue damage at this early time, well before symptoms occur, could allow doctors to tailor interventions which could include patient therapies that would reduce or prevent the problems that occur due to radiotherapy of their cancer.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Currently, a patient's risk for toxicity is based almost exclusively on population statistics.
Radiation (and chemotherapy) doses are based on phase I data and not on the individual's specific genetics or hidden predispositions.
RadTox measures cell damage as early as after the 2nd but before the 4th radiotherapy dose during week 1 of radiotherapy and should help identify patients at high risk for radiation complications.
This should allow physicians to adjust radiation field size and dose to minimize long-term toxicity, especially gastrointestinal toxicities.
Study Type
Observational
Enrollment (Estimated)
250
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ann K Vallerga, PhD, MBA
- Phone Number: 650-333-3152
- Email: annek@diacarta.com
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Recruiting
- University of Florida, Gainesville, FL
-
Contact:
- Jessica Kirwan
- Phone Number: 352-265-8832
- Email: kirwaj@shands.ufl.edu
-
Principal Investigator:
- Randal H Henderson, MD, MBA
-
Jacksonville, Florida, United States, 32206
- Recruiting
- UF Health Proton Therapy Institute
-
Principal Investigator:
- Randal H Henderson, MD, MBA
-
Contact:
- Robin Cacchio, RN, CCRP
- Phone Number: 904-588-1460
- Email: rcacchio@floridaproton.org
-
-
New York
-
Bronx, New York, United States, 10469
- Recruiting
- NY Cancer and Blood Specialists
-
Contact:
- Carmen Vicuna, CRC
- Phone Number: 718-732-4078
- Email: cvicuna@nycancer.com
-
Principal Investigator:
- Richard Zuniga, MD
-
New York, New York, United States, 10028
- Recruiting
- NY Cancer and Blood Specialists
-
Contact:
- Carissa Pedersen, LPN
- Phone Number: 917-258-7633
- Email: cpedersen@nycancer.com
-
Principal Investigator:
- Richard Zuniga, MD
-
Port Jefferson Station, New York, United States, 11776
- Recruiting
- NY Cancer and Blood Specialists
-
Contact:
- Joseph Battelli, BS, MS
- Phone Number: 631-675-5335
- Email: jbattelli@nycancer.com
-
Principal Investigator:
- Richard Zuniga, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
28 years to 83 years (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
Male patients with undergoing radiation therapy for prostate cancer
Description
Inclusion Criteria:
- Men diagnosed with adenocarcinoma of the prostate who have not received previous treatment (defined as prostatectomy, transurethral resection of the prostate [TURP], radiation of the pelvis, and GreenLight Laser Therapy) except for short-term (≤6 months) Androgen Deprivation Therapy (ADT) according to National Comprehensive Cancer Network (NCCN) guidelines.
- Candidate for definitive prostate radiotherapy (either IMRT or proton).
- Patients to be treated with IMRT should have all radiation treatment planned with IMRT, whereas patients to be treated with protons should have all radiation treatment planned with protons (including pelvic nodes if treated).
- Localized prostate cancer, as confirmed by staging with Prostate-Specific Antigen (PSA), biopsy, Gleason score, and clinical stage.
- Nuclear medicine bone imaging is required for confirmation of the absence of overt metastatic disease in bones if any high-risk criteria are identified (clinical stage T3a or higher; or 1-4 cores of Gleason score 8 [NCCN Grade Group 4] or 4+5; or PSA ≥20 ng/mL).
- Diagnosed with any of the NCCN initial groups (i.e., Very-Low-Risk, Low-Risk, Intermediate-Risk [both Favorable and Non-Favorable Intermediate-Risk]; High-Risk; or Very-High-Risk) (see Appendix III for NCCN classifications of various risk groups). For Very-High-Risk, subjects are to have negative prostate cancer specific PET/CT imaging for confirmation of being metastasis free.
- The score for Question 16 (i.e., "Overall, how big a problem have your bowel habits been for you during the last 4 weeks?") of the Bowel Habits section of Expanded Prostate Cancer Index Composite (EPIC) questionnaire must be 2 or below.
- 30-85 years of age at the time of consent.
- Eastern Cooperative Oncology Group (ECOG)/Zubrod Performance Status 0 - 2.
Exclusion Criteria:
- Findings of metastatic disease (nodal or distant, >N1 or M1).
- Prior prostatectomy, TURP, radiation of the pelvis, or GreenLight Laser Therapy.
- History of invasive rectal malignancy or other pelvic malignancy, regardless of disease-free interval.
- The score for Question 16 (i.e., "Overall, how big a problem have your bowel habits been for you during the last 4 weeks?") of EPIC questionnaire is 3 or above.
- Active inflammatory bowel disease (i.e., patients requiring medical interventions or who are symptomatic) or documented history of inflammatory bowel disease requiring intervention.
- Prior pelvic radiotherapy for any reason.
- Documented lack of psychological ability or general health permitting completion of the study requirements and required follow-up.
- Documented decisionally impaired persons who have a diminished capacity to understand the risks and benefits of participation in research and to autonomously provide informed consent.
- Subjects who participated in a clinical trial of an investigational device, drug or biologics within the past 30 days.
- Subjects who are currently undergoing any cancer drug treatment. However, patients who had received cancer drug treatment and stopped the treatment for >4 weeks prior to the start of radiotherapy can be included. (Hormone therapy is allowed if judged appropriate and necessary by the treating physicians.)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Evaluate toxicity biomarkers
Investigators will determine if measurement of circulating DNA from normal tissues shortly after the start of radiotherapy provides an early indication of patients at high risk of radiation-related toxicity.
Blood specimens for RadTox test will be collected: (a) prior to radiotherapy (T0); (b) after the 2nd but before the 4th radiotherapy dose during week 1 (T1); (c) on Week 2 during radiotherapy (T2); and (d) 3 months after completion of radiotherapy (T3).
|
Collection of plasma samples - Plasma samples are collected at different times during the study for the RadTox test.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the cut-off values from the RadTox test results during early radiation treatment from all evaluable subjects to differentiate high toxicity score from average or low toxicity score.
Time Frame: 1 year after radiotherapy
|
The cut-off values of all evaluable subjects will be measured based on the Receiver Operating Characteristic (ROC) analysis to optimize detection of true high-risk patients with ≥60% sensitivity and ≥60% specificity allowing for an acceptable number of high-risk classified but normal-risk patients.
|
1 year after radiotherapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the cut-off values from the RadTox test performed during early radiation treatment with patients categorized according to demographics and treatment options to differentiate high toxicity score from average or low toxicity score.
Time Frame: 1 year after radiotherapy
|
The RadTox test results will be measured to determine the cut-off values according of patients' demographics and treatment options such as fractionation and radiation modality.
|
1 year after radiotherapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2020
Primary Completion (Estimated)
September 6, 2023
Study Completion (Estimated)
December 31, 2023
Study Registration Dates
First Submitted
October 2, 2020
First Submitted That Met QC Criteria
October 2, 2020
First Posted (Actual)
October 8, 2020
Study Record Updates
Last Update Posted (Actual)
September 7, 2023
Last Update Submitted That Met QC Criteria
September 6, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DIA.0009
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
Clinical Trials on Collection of plasma samples
-
Gdansk University of Physical Education and SportCompletedCoronary DiseasePoland
-
Jules Bordet InstituteBristol-Myers Squibb; La Fondation contre le cancer, Belgique; Les Amis de l'Institut... and other collaboratorsRecruitingCNS MetastasesBelgium, France, Luxembourg
-
British Columbia Cancer AgencyAmerican Society of Clinical Oncology; BC Cancer Foundation; Terry Fox Research... and other collaboratorsRecruitingCancer | Pancreatic CancerCanada
-
Centre Hospitalier Universitaire de NiceCompletedUrinary Tract InfectionsFrance
-
University of FloridaNational Institutes of Health (NIH); DiaCarta, Inc.Completed
-
Innovaderm Research Inc.RecruitingPlaque Psoriasis | Atopic Dermatitis | Hidradenitis Suppurativa | Palmoplantar Pustulosis | Acne | Chronic Hand EczemaCanada
-
Institut National de la Santé Et de la Recherche...Not yet recruitingAutoimmune Diseases | Systemic Lupus Erythematosus | Primary Immunodeficiency | Autoimmune Hepatitis | Juvenile Idiopathic Arthritis | IBD | Autoimmune Rheumatologic Disease | Autoimmune Diabetes | APECED | IPEX | Hemophagocytic Lymphohistiocytoses | Autoimmune Lymphoproliferative Syndrome | Autoimmune Thrombocytopenia and other conditions
-
Centre Hospitalier René DubosCompletedCoronavirus InfectionFrance
-
Haemonetics CorporationCompletedApheresis Related HypotensionUnited States
-
Centre Francois BaclesseLigue contre le cancer, France; Fondation de France; Centre National de la Recherche...Recruiting